FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3207699404> ?p ?o ?g. }

• W3207699404 endingPage "3051" @default.
• W3207699404 startingPage "3034" @default.
• W3207699404 abstract "The antimicrobial medication malarone (atovaquone/proguanil) is used as a fixed-dose combination for treating children and adults with uncomplicated malaria or as chemoprophylaxis for preventing malaria in travelers. It is an inexpensive, efficacious, and safe drug frequently prescribed around the world. Following anecdotal evidence from 17 patients in the provinces of Quebec and Ontario, Canada, suggesting that malarone/atovaquone may present some benefits in protecting against COVID-19, we sought to examine its antiviral potential in limiting the replication of SARS-CoV-2 in cellular models of infection. In VeroE6 expressing human TMPRSS2 and human lung Calu-3 epithelial cells, we show that the active compound atovaquone at micromolar concentrations potently inhibits the replication of SARS-CoV-2 and other variants of concern including the alpha, beta, and delta variants. Importantly, atovaquone retained its full antiviral activity in a primary human airway epithelium cell culture model. Mechanistically, we demonstrate that the atovaquone antiviral activity against SARS-CoV-2 is partially dependent on the expression of TMPRSS2 and that the drug can disrupt the interaction of the spike protein with the viral receptor, ACE2. Additionally, spike-mediated membrane fusion was also reduced in the presence of atovaquone. In the United States, two clinical trials of atovaquone administered alone or in combination with azithromycin were initiated in 2020. While we await the results of these trials, our findings in cellular infection models demonstrate that atovaquone is a potent antiviral FDA-approved drug against SARS-CoV-2 and other variants of concern in vitro." @default.
• W3207699404 created "2021-10-25" @default.
• W3207699404 creator A5000811036 @default.
• W3207699404 creator A5004521226 @default.
• W3207699404 creator A5012677572 @default.
• W3207699404 creator A5013926332 @default.
• W3207699404 creator A5018315917 @default.
• W3207699404 creator A5019972847 @default.
• W3207699404 creator A5020010668 @default.
• W3207699404 creator A5026081262 @default.
• W3207699404 creator A5026781059 @default.
• W3207699404 creator A5032724762 @default.
• W3207699404 creator A5033739590 @default.
• W3207699404 creator A5042737704 @default.
• W3207699404 creator A5043573924 @default.
• W3207699404 creator A5044305087 @default.
• W3207699404 creator A5048499215 @default.
• W3207699404 creator A5054322266 @default.
• W3207699404 creator A5054986019 @default.
• W3207699404 creator A5056426167 @default.
• W3207699404 creator A5057374826 @default.
• W3207699404 creator A5060792680 @default.
• W3207699404 creator A5063568342 @default.
• W3207699404 creator A5064287991 @default.
• W3207699404 creator A5065448222 @default.
• W3207699404 creator A5074354899 @default.
• W3207699404 creator A5075299590 @default.
• W3207699404 creator A5081264939 @default.
• W3207699404 creator A5082089381 @default.
• W3207699404 creator A5083273777 @default.
• W3207699404 creator A5083436266 @default.
• W3207699404 creator A5090816818 @default.
• W3207699404 date "2021-10-18" @default.
• W3207699404 modified "2023-10-15" @default.
• W3207699404 title "Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern" @default.
• W3207699404 cites W1925670668 @default.
• W3207699404 cites W1976977157 @default.
• W3207699404 cites W1983804855 @default.
• W3207699404 cites W1987070293 @default.
• W3207699404 cites W1998964868 @default.
• W3207699404 cites W2007561244 @default.
• W3207699404 cites W2012789887 @default.
• W3207699404 cites W2025605230 @default.
• W3207699404 cites W2139271485 @default.
• W3207699404 cites W2168903926 @default.
• W3207699404 cites W2169100396 @default.
• W3207699404 cites W2256756668 @default.
• W3207699404 cites W2298279719 @default.
• W3207699404 cites W2762941703 @default.
• W3207699404 cites W2888230285 @default.
• W3207699404 cites W2920952239 @default.
• W3207699404 cites W2970965831 @default.
• W3207699404 cites W3013800395 @default.
• W3207699404 cites W3020710323 @default.
• W3207699404 cites W3080981445 @default.
• W3207699404 cites W3083929515 @default.
• W3207699404 cites W3091428163 @default.
• W3207699404 cites W3105908160 @default.
• W3207699404 cites W3111255098 @default.
• W3207699404 cites W3111590711 @default.
• W3207699404 cites W3112772443 @default.
• W3207699404 cites W3113848502 @default.
• W3207699404 cites W3119345685 @default.
• W3207699404 cites W3130774774 @default.
• W3207699404 cites W3135769626 @default.
• W3207699404 cites W3137359073 @default.
• W3207699404 cites W3156173251 @default.
• W3207699404 cites W4205483821 @default.
• W3207699404 cites W4234790212 @default.
• W3207699404 doi "https://doi.org/10.1021/acsinfecdis.1c00278" @default.
• W3207699404 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8547501" @default.
• W3207699404 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34658235" @default.
• W3207699404 hasPublicationYear "2021" @default.
• W3207699404 type Work @default.
• W3207699404 sameAs 3207699404 @default.
• W3207699404 citedByCount "15" @default.
• W3207699404 countsByYear W32076994042021 @default.
• W3207699404 countsByYear W32076994042022 @default.
• W3207699404 countsByYear W32076994042023 @default.
• W3207699404 crossrefType "journal-article" @default.
• W3207699404 hasAuthorship W3207699404A5000811036 @default.
• W3207699404 hasAuthorship W3207699404A5004521226 @default.
• W3207699404 hasAuthorship W3207699404A5012677572 @default.
• W3207699404 hasAuthorship W3207699404A5013926332 @default.
• W3207699404 hasAuthorship W3207699404A5018315917 @default.
• W3207699404 hasAuthorship W3207699404A5019972847 @default.
• W3207699404 hasAuthorship W3207699404A5020010668 @default.
• W3207699404 hasAuthorship W3207699404A5026081262 @default.
• W3207699404 hasAuthorship W3207699404A5026781059 @default.
• W3207699404 hasAuthorship W3207699404A5032724762 @default.
• W3207699404 hasAuthorship W3207699404A5033739590 @default.
• W3207699404 hasAuthorship W3207699404A5042737704 @default.
• W3207699404 hasAuthorship W3207699404A5043573924 @default.
• W3207699404 hasAuthorship W3207699404A5044305087 @default.
• W3207699404 hasAuthorship W3207699404A5048499215 @default.
• W3207699404 hasAuthorship W3207699404A5054322266 @default.
• W3207699404 hasAuthorship W3207699404A5054986019 @default.
• W3207699404 hasAuthorship W3207699404A5056426167 @default.

• next